Nuvectis Pharma (NVCT) Shares Outstanding (Weighted Average) (2021 - 2026)

Nuvectis Pharma has disclosed Shares Outstanding (Weighted Average) across 6 years of filings, most recently posting $26.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $26.4 million, up 32.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.4 million (up 32.64% YoY), and the FY2025 annual result was $21.8 million, up 27.46% from the prior year.
• Shares Outstanding (Weighted Average) came in at $26.4 million for Q1 2026 at Nuvectis Pharma, up from $21.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $26.4 million in Q1 2026 to a low of $9.2 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $16.6 million (2024), against an average of $16.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 206.04% in 2022 and advanced 6.99% in 2024, its largest moves.
• Nuvectis Pharma's Shares Outstanding (Weighted Average) stood at $12.7 million in 2022, then climbed by 22.9% to $15.6 million in 2023, then grew by 10.01% to $17.1 million in 2024, then climbed by 27.46% to $21.8 million in 2025, then climbed by 21.24% to $26.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $26.4 million (Q1 2026), $21.8 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.